SCHEDULE: Vanguard Group Divests Apellis Stake to 0% Post-Realignment

The Vanguard Group reported a 0% beneficial ownership in Apellis Pharmaceuticals Inc. common stock following an internal corporate realignment.

Summary

• The Vanguard Group filed an Amendment No. 4 to Schedule 13G regarding its beneficial ownership in Apellis Pharmaceuticals Inc.
• As of March 13, 2026, The Vanguard Group reported 0.00 shares beneficially owned, representing 0% of the class.
• This change is due to an internal realignment on January 12, 2026, where certain subsidiaries and business divisions will now report beneficial ownership separately.
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over these disaggregated securities.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral for Apellis Pharmaceuticals Inc., as it primarily reflects an internal organizational and reporting change by The Vanguard Group rather than a direct investment decision or operational update for Apellis.

Positives

• Increased transparency in beneficial ownership reporting as Vanguard's subsidiaries will now report separately.

Negatives

• The Vanguard Group no longer holds beneficial ownership of Apellis Pharmaceuticals Inc. common stock under its primary reporting entity.

Risks

• NA

Future Outlook

NA

Management Comments

• On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release.
• These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment.
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are routine disclosures for institutional investors. This specific amendment reflects an internal organizational change at The Vanguard Group, a major asset manager, rather than a strategic investment decision related to Apellis Pharmaceuticals Inc. It highlights the ongoing evolution of reporting requirements and internal structures within large financial institutions.

Corporate Governance

Stakeholder Impact

• Shareholders (Apellis): No direct operational or financial impact on Apellis shareholders. The change is purely in how Vanguard's holdings are reported.
• Investors (Vanguard funds): Provides clearer, disaggregated reporting of beneficial ownership by specific Vanguard entities.

Next Steps

• Vanguard's subsidiaries or business divisions will now report their beneficial ownership in Apellis Pharmaceuticals Inc. separately.

Key Dates

Keywords

Apellis Pharmaceuticals, Vanguard Group, Schedule 13G, beneficial ownership, common stock, SEC filing, investment adviser, corporate realignment